TEM's strong data licensing growth, AI-driven innovations and rising shares favor holding the stock,

Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene

Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS serv

Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential

CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration

S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellat

Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect

TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardia

Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accen

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors headin

Guggenheim analyst Subbu Nambi maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price t

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been

Strong performance across the healthtech sector over the past two quarters has sparked renewed marke

ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pu

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clear

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the busine

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and

The transaction involved 7,062 shares with an estimated value of $529,650 as of the transaction date

AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision

Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI M

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Louis says buy the AI dip

Tempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth

Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding d

Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance w

Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursi

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data lic

Wall Street initiated coverage on XRN, TEM, NNE, SECZ with ratings from Neutral to Buy and price tar

Goldman Sachs analyst Evie Koslosky initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral r

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Ryan Fukushima sold 700 shares of the firm's sto

Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally stil

Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike an

U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

CNBC’s final trades: Joshua Brown picked Snowflake, Bill Baruch chose Tempus AI, Malcolm Ethridge fa

The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longi

HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises th

Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Pro

UBS analyst Doug Schenkel initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and

Rothschild & Co analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutr

Roth Capital analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rati

Tempus AI receives an Overweight rating and $80 price target from Cantor Fitzgerald, which sees sign

Cantor Fitzgerald analyst Sarah James initiates coverage on Tempus AI (NASDAQ:TEM) with a Overwei

Ark Invest sold $15.6 million of Tempus AI and $3.4 million of AMD on Tuesday, Sept. 1, 2026.

Piper Sandler analyst David Westenberg upgrades Tempus AI (NASDAQ:TEM) from Neutral to Overweight

Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the fu

Freedom Capital Markets analyst Gene Mannheimer maintains Tempus AI (NASDAQ:TEM) with a Hold and

Ark Invest bought roughly $17 million in Cerebras shares Tuesday, Aug. 25, 2026, while trimming its